Scholar Rock (SRRK) Q2 2026 earnings summary

Executive summary

• Apitegromab, the first muscle-targeted therapy for SMA, is under FDA review with a PDUFA date of September 30, 2026, and commercialization readiness in the U.S. and Europe, including Germany and a planned 50-country platform.

• Positive Phase 3 SAPPHIRE results for apitegromab in SMA; BLA resubmitted after CRL due to third-party fill-finish facility issues.

• Two fill-finish facilities included in the BLA provide independent FDA approval paths, with the second facility now supplying more launch-ready vials than Catalent, Indiana.

• Robust anti-myostatin pipeline progress, including Phase 2 studies in SMA and FSHD, and a Phase 1 study for SRK-439.

• No product revenue to date; operations funded by equity, debt, and collaborations.

Financial highlights

• Ended Q2 2026 with $492.1 million in cash, cash equivalents, and marketable securities, up from $367.6 million at year-end 2025.

• Net loss for Q2 2026 was $109.9 million, and $215.4 million for the six months ended June 30, 2026.

• Q2 operating expenses were $108.9 million, including $19.7 million in non-cash stock-based compensation; six-month operating expenses rose 11.5% to $210.9 million.

• Raised $63 million in net proceeds from the ATM program during Q2 2026, and $160.8 million through ATM equity sales in H1 2026.

• $200 million drawn from Blue Owl debt facility in 2026, with up to $350 million available.

Outlook and guidance

• On track for FDA decision by September 30, 2026, with immediate U.S. launch readiness and advancing European preparations.

• EMA approval in Europe depends on FDA classification of Catalent, Indiana, but engagement is ongoing to include the second facility if needed.

• Existing cash and securities expected to fund operations into the second half of 2027, but additional capital will be required for full commercialization.